Mireia Bachiller

Regulatory Affairs in Advanced Therapies at Hospital Clinic de Barcelona.

[SoniaGuedan @GuedanS]

💉 For those colleagues attending the 7th European CAR T-cell Meeting of the @EHA_Hematology and @TheEBMT in 🇫🇷 Strasbourg, I’ll be presenting Next-generation CAR-T cells for solid tumors and hematological malignancies in Room Schweitzer, from 9:30 to 10:30 h. Come say hi!

[SoniaGuedan @GuedanS]

🏥 This therapy developed at @idibaps is now in clinical trials at @hospitalclinic de Barcelona. We hope this contributes not only to advancing research but also to making CAR-T cell therapy more understandable and accessible.

Together, we keep moving forward!

[Alex Rampotas @ARampotas]

Bye bye, bispecific? Check out our commentary on the development of a CD19/BCMA dual targeting CAR-T for non-Hodgkin Lymphoma led by Bachiller et al.

@GuedanS
@MolTherapy

Co-transduction for the win! Link below ⬇️ for free access https://t.co/8f5q92fXs0…
@drclaireroddie

[Mireia Bachiller @bachillermireia]

Our work is now published in @MolTherapy! Here we characterize ARI0003, a co-transduced CAR-T cell therapy targeting CD19/BCMA for B-NHL. Special thanks to my mentors @GuedanS and @UrbanoIspizuaMD, and to my amazing co-authors Nina Barceló and @Alba_rodriguezg.

[SoniaGuedan @GuedanS]

Our latest work is out in @MolTherapy! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation.
➡️ https://t.co/yMhjCAjyaq

[Alba Rodríguez @Alba_rodriguezg]

Check out our new paper in @MolTherapy! Congrats @bachillermireia and Nina for the hard work 💪🏽💪🏽

[ASGCT @ASGCTherapy]

On Friday, Nov. 8, @FDA approved #obecel for B-cell #acutelymphoblasticleukemia (#ALL) Obe-cel is a CD19 CAR T-cell investigational therapy designed with a fast target binding off-rate to minimize excessive activation of the programmed T cells. https://t.co/mbeT953mTt

[Hospital Clínic @hospitalclinic]

🏥 Luz verde al CAR-T ARI0002h desarrollado por el #CLÍNIC-@idibaps para pacientes con #mielomamúltiple en recaída.

✅ El Comité de @AEMPSGOB ha dado el visto bueno para aprobarlo como medicamento de terapia avanzada de fabricación no industrial.

👉 https://t.co/PMB0jFWJAW

[Amics del CLÍNIC @AmicsdelCLINIC]

🔬 L’@hospitalclinic-@idibaps ha iniciat un #assaigclínic amb l’ARI-0003 per a limfoma. L’avantatge amb aquest CAR-T és que s’ha dissenyat amb diversos centres, i per tant tindrà una distribuci�� més alta.

🤝 Col·labora amb el #ProjecteARI 👉 https://t.co/b6rQbhHDdZ

[Julio Delgado @JulioDelgadoHem]

Today, at TLH, we summarise a decade of hard work. We wish to thank all colleagues, patients and relatives, who helped us during this amazing journey.
https://t.co/CIzVqbLH3m

[U.S. FDA @FDA]

Today, FDA expanded the approval of a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. https://t.co/JUB7nWyuch

[SoniaGuedan @GuedanS]

💉 In collaboration with @SETGyC, our colleagues from @HospitalUVRocio and @ibis_sevilla are organizing the PhD training day "CARTcell: from bench to bedside" in Seville on Sep 19-20.

✈️ From the @SETGYC, we are offering 15 travel grants. Take a look! ➡️ https://t.co/6jM9120VQp

[SoniaGuedan @GuedanS]

💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in @NatureComms unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️

[Beatriz Martin Antonio @Beatriz15995013]

We are looking for a motivated PhD candidate to start researching in CAR-T cell immunotherapy. Initially, we offer a 6-month contract to learn and to apply during that time to additional grants to do the PhD.
For additional information:
https://t.co/lUoPbFfC5X

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

Barcelona calling for the first multinational, fully academic, CART trial with the academic #ARI0001 (var-cel) CART19 for adult patients with high-risk / refractory B-ALL (CART19-EU-04 trial). This is, academic European institutions making a bit of history! 🤝 🇪🇦🇨🇵🇱🇺🇦🇹 +

[Carlos Fernandez de Larrea @fdezdelarrea]

Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma https://t.co/sx8x9di0eL

[Evan Weber @EvanWeberPhD]

Memory genes are enriched in CAR T cells that persist and control tumors in patients. But which transcription factors drive beneficial memory programs?

We answer this in our lab’s first paper in @Nature led by @alexdoan96 @kpmueller1 @andy_yhchen. 1/

https://t.co/qvTdqoeduz

[Hospital Clínic @hospitalclinic]

🔬 Durante la presentación se ha anunciado que, gracias al impulso del #ProjecteARI, se iniciará un ensayo con un CAR-T dual, el ARI-0003, para el tratamiento de #linfomas.

💊Participarán 3⃣5⃣ pacientes y empezará en las próximas semanas.

[SETGyC @SETGyC]

En la @SETGyC estamos orgullosos de contar con tantas científicas brillantes, entregadas a la investigación y con activa participación.

Queremos dar un especial reconocimiento a todas las socias junior, investigadoras del presente y próximas referentes en las terapias avanzadas.

[Pau Alcubilla @paualcu]

Si algun #mir2024 creu que li pot interessar l'especialitat de Farmacologia Clínica en general, i a l'@hospitalclinic en particular, que ens contacti! Som pocs i ningú sap ben bé què fem, però som majos.
@lulaare @PenataroSaez @victoriaanl_ @JuanCionaig @LinaLeguizamo2

[SoniaGuedan @GuedanS]

👩‍🔬 Celebrating the brilliance, curiosity and resilience of women and girls in science on this International Day of Women and Girls in Science.

🔬 Big shoutout to the talented and hardworking scientists in my group and beyond. We celebrate it today, and we remain aware every day.